Science Advances

Supplementary Materials

This PDF file includes:

  • fig. S1. The tumor-homing peptides FAM-CGKRK and FAM-iRGD do not accumulate in maternal organs of pregnant mice.
  • fig. S2. FAM-CGKRK and FAM-iRGD colocalize with endothelial cell and trophoblast markers in the mouse placenta.
  • fig. S3. FAM-CGKRK and FAM-iRGD colocalize with markers of the mouse placental labyrinth.
  • fig. S4. Administration of placental homing peptides does not alter cell turnover in the developing mouse placenta.
  • fig. S5. FAM-CGKRK and FAM-iRGD colocalize with markers villous trophoblast.
  • fig. S6. FAM-iRGD colocalizes with αV integrin in mouse decidual spiral arteries.
  • fig. S7. Calreticulin knockdown in the STB layer of human term placental explants.
  • fig. S8. Biodistribution of tumor-homing peptide–decorated nanoworms in pregnant mice.
  • fig. S9. Biodistribution of tumor-homing peptide–decorated liposomes in pregnant mice after 24 hours.
  • fig. S10. Biodistribution of tumor-homing peptide–decorated liposomes in pregnant mice after 72 hours.
  • fig. S11. Biodistribution of liposomes decorated with a control peptide in pregnant mice.
  • fig. S12. Biodistribution of plain liposomes (no targeting peptide) in pregnant mice.
  • fig. S13. Targeted delivery of IGF-2 to wild-type C57BL/6J mice does not alter litter size, resorption number, or weight of maternal clearance organs.
  • fig. S14. Targeted delivery of IGF-2 to P0 mice does not alter litter size, resorption number, or weight of maternal clearance organs.

Download PDF

Files in this Data Supplement: